Lenadogene neparvovec (Lumevoq) gene therapy is designed to treat vision loss caused by Leber hereditary optic neuropathy, a mitochondrial genetic disease. The disease mainly affects young boys and most patients become legally blind.

The application was submitted with assistance from regulatory consulting group Diamond Pharma Services. Diamond provided GenSight with regulatory, preparation, authoring, and quality and compliance support, according to the company.

GenSight and Diamond expect a decision from the EMA in late 2021. GenSight is headquartered in Paris and focuses on the development and commercialization of gene therapies for retinal neurodegenerative diseases and central nervous system disorders.

Neurophth's gene therapy granted orphan drug designation
Neurophth Therapeutics' lead candidate, NR082, an adeno-associated virus-based gene therapy, has been granted orphan drug designation by the U.S. Food...

Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...